---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-225406"
form_type: "8-K"
ticker: null
cik: "0001597553"
company_name: "Sage Therapeutics, Inc."
filed_at: "2023-08-31T23:59:59+00:00"
generated_at: "2026-06-11T01:12:58.843666+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sage Therapeutics to cut ~40% of workforce, focus on zuranolone launch and SAGE-718/324

## Summary
- Workforce reduction of ~40%; expected severance charge of $36M-$38M in Q3 2023.
- Pipeline prioritization: focus on SAGE-718 and SAGE-324; earlier-stage programs paused.
- Planned commercial launch of ZURZUVAE (zuranolone) for postpartum depression in late 2023.
- Cash, equivalents, and marketable securities ~$1.0B as of June 30, 2023; expected to fund operations into 2026.
- Leadership team realigned to support pipeline and commercial priorities.

## SEC filing metadata
- accession: 0001193125-23-225406
- form_type: 8-K
- cik: 0001597553
- company_name: Sage Therapeutics, Inc.
- filed_at: 2023-08-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1597553/000119312523225406/0001193125-23-225406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1597553/000119312523225406/d530485d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-225406
- JSON: https://secwatch.observer/filing/0001193125-23-225406.json
- Plain text: https://secwatch.observer/filing/0001193125-23-225406.txt

## Key facts
- Restructurings & Charges
  Sage Therapeutics, Inc. announced a restructuring with charges of approximately $36 million to $38 million affecting the Company (approximately 40%).
  - Type: restructuring
  - Charge: approximately $36 million to $38 million
  - Affected area: the Company
  - Headcount: approximately 40%
  source text: On August 28, 2023, Sage Therapeutics, Inc. (the “Company”) committed to a plan to reorganize the Company’s business operations and pipeline priorities in order to support goals for long-term business growth, including the planned commercial launch of ZURZUVAE TM (zuranolone) for the treatment of adults with postpartum depression (“PPD”) in late 2023. As part of the reorganization, the Company plans to focus its development efforts on its product candidates SAGE-718 and SAGE-324, pause certain earlier-stage programs, implement a reduction of the Company’s workforce by approximately 40%, and align its leadership team structure to scale with its pipeline and commercial priorities. The Company expects a non-recurring charge for severance and related employee costs associated with the workforce reduction of approximately $36 million to $38 million, primarily incurred in the third quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1597553/000119312523225406/0001193125-23-225406-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.